Skip to main content

Table 3 Characteristics of the patient group

From: Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants

VariableAll geocoded patients (N = 6519)Warfarin (N = 4560)DOACs (N = 1239)No medication (N = 720)
Age, mean (SD)76.5 (10.5)78.1 (9.4)75.1 (10.1)68.5 (13.5)
Retired, age ≥ 63 years, n (%)5896 (90.5)4302 (94.3)1103 (89.0)491 (68.2)
Gender, male, n (%)3532 (54.2)2388 (52.4)663 (53.5)481 (66.8)
BMI, mean (SD)29.1 (6.2)29.3 (6.4)29.3 (5.8)28.1 (5.4)
Obesity (BMI > 30), n (%)1456 (22.3)1006 (22.1)327 (26.4)123 (17.1)
CHA2DS2-VASc, mean (SD)a3.1 (1.6)3.3 (1.5)3.1 (1.6)1.9 (1.6)
Diabetes, n (%)1648 (25.3)1210 (26.5)315 (25.4)123 (17.1)
Hypertension, n (%)3261 (50.0)2302 (50.5)696 (56.2)263 (36.5)
Vascular disease, n (%)b1657 (25.4)1219 (26.7)323 (26.1)115 (16.0)
Congestive heart failure, n (%)976 (15.0)771 (16.9)161 (13.0)44 (6.1)
Transient ischemic attack (TIA), n (%)271 (4.2)188 (4.1)73 (5.9)10 (1.4)
Home address in assisted living building, n (%)765 (11.7)599 (13.1)93 (7.5)73 (10.1)
Number of INR measurements in 2017, mean (SD)15.4 (11.0)15.9 (10.9)  
Standard TTR definable in 2017, n (%)3524 (54.1)3307 (72.5)  
  1. aAnticoagulation medication should be used for patients having the score of 2 or more
  2. bVascular disease includes the following ICD-10 codes: I20-I25, I70.9